Influenza virus vaccine quadrivalent - Protein Sciences Corporation

Drug Profile

Influenza virus vaccine quadrivalent - Protein Sciences Corporation

Alternative Names: FluBlok Quadrivalent; FluBlok-Q; PSC Flu vaccine (4 strains); Quadrivalent recombinant influenza vaccine seasonal – Protein Sciences Corporation; RIV4; Seasonal quadrivalent influenza vaccine – Protein Sciences Corporation

Latest Information Update: 05 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protein Sciences Corporation
  • Developer Laboratorios Liomont; Protein Sciences Corporation
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 22 Mar 2018 Phase-III clinical trials in Influenza virus infections prevention (In children, In adolescents, Prevention) in Mexico (IM) (NCT03460743)
  • 04 Jan 2018 inVentiv Health has merged with INC Research to form Syneos Health
  • 28 Aug 2017 Protein Sciences Corporation has been acquired by Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top